Erratum to: Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials

Antonin Levy · Laurence Albiges-Sauvin · Christophe Massard · Hassan Izzedine · Stéphane Ederhy · Ratio Bahleda · Carlos Gomez-Roca · Cyrus Chargari · Isabelle Brocheriou-Spelle · Jean-Charles Soria

Published online: 3 January 2012
© Springer Science+Business Media, LLC 2011

Erratum to: Invest New Drugs
DOI 10.1007/s10637-011-9671-z

We would like to correct one Author's name on our manuscript:
-Stéphane Ederhy (instead of Stéphane Edhery)

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-011-9671-z>.

A. Levy · L. Albiges-Sauvin · C. Massard · S. Ederhy ·
R. Bahleda · C. Gomez-Roca · J.-C. Soria (✉)
SITEP (Service des Innovations Thérapeutiques Précoces),
Department of Medicine, Institut Gustave Roussy,
Paris XI University,
114 rue Edouard Vaillant,
94805 Villejuif, France
e-mail: soria@igr.fr

A. Levy · C. Chargari
Inserm 1030, Institut Gustave Roussy, Paris XI University,
Villejuif, France

H. Izzedine
Department of Nephrology, AP-HP, Hôpital Pitié Salpêtrière,
Paris, France

I. Brocheriou-Spelle
Department of Pathology, AP-HP, Hôpital Pitié Salpêtrière,
Paris, France